Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Science Translational Medicine

• Publication date

  2012-03-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/scitranslmed.3003689PMID 22461641PMCID PMC3568523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An immune-active tumor microenvironment favors clinical response to ipilimumab

  2012cited by this paper
• PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature.

  2011cited by this paper
• Overall survival and PD‐L1 expression in metastasized malignant melanoma

  2011cited by this paper
• Cancer immunotherapy comes of age.

  2011cited by this paper
• Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

  2009cited by this paper
• Final version of 2009 AJCC melanoma staging and classification.

  2009cited by this paper
• The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

  2008cited by this paper
• Inhibitory B7-family molecules in the tumour microenvironment

  2008cited by this paper
• Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

  2008cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy

  2007cited by this paper
• The new B7s: playing a pivotal role in tumor immunity.

  2007cited by this paper
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

  2007cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• Mononuclear cell infiltration in clear‐cell renal cell carcinoma independently predicts patient survival

  2006cited by this paper
• Somatic activation of KIT in distinct subtypes of melanoma.

  2006cited by this paper
• The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

  2006cited by this paper
• Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.

  2006cited by this paper
• Distinct sets of genetic alterations in melanoma.

  2005cited by this paper
• Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

  2005cited by this paper
• Effector memory T cells, early metastasis, and survival in colorectal cancer.

  2005cited by this paper
• B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.

  2004cited by this paper
• CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma

  2004cited by this paper
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

  2004cited by this paper
• Costimulatory B 7-H 1 in renal cell carcinoma patients : Indicator of tumor aggressiveness and potential therapeutic target

  2004cited by this paper
• Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1

  2003cited by this paper
• Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

  2003cited by this paper
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

  2003cited by this paper
• Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002influential reference
• Expression of Programmed Death 1 Ligands by Murine T Cells and APC1

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Comprehensive analysis of the frequency of recognition of melanoma‐associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy

  2001cited by this paper
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

  2001cited by this paper
• Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.

  2001cited by this paper
• A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma.

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.

  1999cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.

  1996cited by this paper
• Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

  1996cited by this paper
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

  1995cited by this paper
• Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

  1995cited by this paper
• Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

  1992cited by this paper

• CD8/CD4 ratio, CD56, and PD-L1 as prognostic markers in sinonasal mucosal melanoma.

  2026cites this paper
• Recent therapeutic advances in gynecologic oncology: evolving roles of immunotherapy, antibody–drug conjugates, and clinical trial innovations

  2026cites this paper
• Checkpoint inhibitors in cancer Immunotherapy: Mechanisms, Resistance, and Combination Strategies

  2026cites this paper
• PD-L1 Expression in Prostate Cancer: Anatomopathological Features, Methodological Pitfalls, and Therapeutic Potential.

  2026cites this paper
• Disrupting Immune Silence: Non-Coding RNAs Targeting the PD-1/PD-L1 Axis in Tumor Immunity

  2026cites this paper
• PROTAC-based protein degradation: a window of opportunity for melanoma therapy

  2026cites this paper
• Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation.

  2026cites this paper
• HPV18-positive Small Cell Neuroendocrine Carcinoma of the Uterine Cervix Treated With Immunotherapy: A Case Report

  2026cites this paper
• A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors

  2026cites this paper
• Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies

  2026cites this paper
• Ultrasound-mediated targeted micro/nanobubbles: breaking new boundaries in precision tumor therapy.

  2026cites this paper
• Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance.

  2026cites this paper
• Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy

  2026cites this paper
• Multiplex immunohistochemistry (IHC) profiling of murine tumour-infiltrating T cells.

  2026cites this paper
• PD-L1 expression and tumor-infiltrating T lymphocytes as prognostic factors in canine mammary tumors.

  2026cites this paper
• Cardiovascular adverse effects of immunotherapy in cancer: insights and implications

  2025cites this paper
• Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review

  2025cites this paper
• Tuning the thermostat. Beyond hot and cold in the medulloblastoma tumor microenvironment

  2025cites this paper
• First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab, in patients with advanced malignancies

  2025cites this paper
• PD-1/PD-L1 inhibitor treatment associated with cardiotoxicity regulated by macrophage polarization and SOCS3/JAK/STAT3 signaling pathway

  2025cites this paper
• Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma

  2025cites this paper
• Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs)

  2025cites this paper
• Sequential JAK inhibition enhances antitumor immunity after combined anti–PD-1 and anti-CTLA4

  2025cites this paper
• Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer: The Clinical Impact of Immune Checkpoint Inhibitors—A Systematic Review

  2025cites this paper
• PD-L1 and the dawn of modern cancer immunotherapy

  2025cites this paper
• Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer

  2025cites this paper
• Cancer cells accelerate exhaustion of persistently activated mouse CD4+ T cells

  2025cites this paper
• Impact of PD-L1 upregulation on immune checkpoint inhibitor efficacy in triple-negative breast cancer using a 4T1 murine model

  2025cites this paper
• Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors.

  2025cites this paper
• Elucidating DNA Damage-Dependent Immune System Activation

  2025cites this paper
• Clinical Approaches for the Management of Skin Cancer: A Review of Current Progress in Diagnosis, Treatment, and Prognosis for Patients with Melanoma

  2025cites this paper
• Esophageal squamous cell carcinoma derived sEV-PDL1 exhausts CD8+T cells to promote immunosuppression.

  2025cites this paper
• Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm

  2025cites this paper
• Prognostic value of immune biomarkers in melanoma loco-regional metastases

  2025cites this paper
• Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach

  2025cites this paper
• Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies.

  2025cites this paper
• The dual role of OTUD3 in cancer: mechanisms and therapeutic implications

  2025cites this paper
• Implementing perioperative immunotherapy for head and neck cancer after KEYNOTE-689: questions and challenges

  2025cites this paper
• Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy

  2025cites this paper
• mRNA Vaccines: Current Applications and Future Directions

  2025cites this paper
• AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer

  2025cites this paper
• Immunophenotypical characterization of immune checkpoint receptor expression in cynomolgus monkeys and human healthy volunteers in resting and in T-cell stimulatory conditions in vitro

  2025cites this paper
• Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics.

  2025cites this paper
• Unleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity.

  2025cites this paper
• Synergistic camrelizumab therapy inhibits P53-mutant osimertinib-resistant solid lung adenocarcinoma via the TGF-β signaling pathway

  2025cites this paper
• Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti-PD-1 Immunotherapy.

  2025cites this paper
• Interferon-induced senescent CD8+ T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer.

  2025cites this paper
• Anti-Cancer and Pro-Immune Effects of Lauric Acid on Colorectal Cancer Cells

  2025cites this paper
• Combined Tumor Infiltrating Lymphocytes and PD‐L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• ZEB1 transcription factor induces tumor cell PD-L1 expression in melanoma

  2025cites this paper
• Combination of Sodium Butyrate and Immunotherapy in Glioma: regulation of immunologically hot and cold tumors via gut microbiota and metabolites

  2025cites this paper
• PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity

  2025cites this paper
• Comparative analysis of PD-L1 expression and tumor-infiltrating lymphocytes between primary breast cancer and matched metastatic lesions: implications for immunotherapy

  2025cites this paper
• Is programmed death-ligand 1 positivity a predictor of poor survival in patients with different histological subtypes of pancreatic cancer?

  2025cites this paper
• Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy

  2025cites this paper
• The change of soluble programmed cell death ligand-1 (sPD-L1): A new predictor of prognosis in hypopharyngeal squamous cell carcinoma patients treated with radiotherapy

  2025cites this paper
• Therapeutic Approaches to Mucosal Melanoma.

  2025cites this paper
• Helicobacter pylori is associated with less tumor-infiltrating lymphocytes and a poor prognosis in gastric cancer

  2025cites this paper
• A new T cell therapy method for cancer: polyclonal effector tumor antigen-specific T cells isolated from autologous blood or lymph nodes by nanoparticles loading whole tumor antigens.

  2025cites this paper
• Immune Biomarkers for Checkpoint Blockade in Solid Tumors: Transitioning from Tissue to Peripheral Blood Monitoring and Future Integrated Strategies

  2025cites this paper
• Intrinsic PDL1 Signaling Modulates TGFBI‐Mediated Growth Suppression in Lung Adenocarcinoma

  2025cites this paper
• A comprehensive insights of cancer immunotherapy resistance

  2025cites this paper
• A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment.

  2025cites this paper
• New trend in molecular diagnostics: Insights from the tumor microenvironment

  2025cites this paper
• Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

  2025cites this paper
• Novel Predictive Spatial Biomarker in Non-Small Cell Lung Carcinoma: The Diversity of Niches Unlocking Treatment Sensitivity (DONUTS)

  2025cites this paper
• Why has immune “checkpoint” therapy failed in most clinical trials?

  2025cites this paper
• Investigation of PD-L1 Expression in Various Non-Hodgkin's B-cell Lymphomas

  2025cites this paper
• NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting

  2025cites this paper
• Dermatotoxicity of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Advances in Mechanistic Insights and Predictive Biomarker Identification

  2025cites this paper
• Skin Immune Responses and Oncogenesis: A Delicate Balance

  2025cites this paper
• 5-Methoxyflavone inhibits the proliferation of lung adenocarcinoma cells through PI3K/AKT/GSK3β/β-catenin/Cyclin D1 signaling and attenuates chemoresistance and PD-L1 expression.

  2025cites this paper
• Lysosome‐Mediated Targeted Protein Degradation: Emerging Chimeric Platforms for Extracellular and Intracellular Therapeutics

  2025cites this paper
• Beyond TIGIT: Lessons from a failed immune checkpoint for rational target discovery.

  2025cites this paper
• The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.

  2024cites this paper
• Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis

  2024cites this paper
• The analysis of multiple omics and examination of pathological images revealed the prognostic and therapeutic significances of CD93 in lung squamous cell carcinoma.

  2024cites this paper
• Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial Relationship

  2024cites this paper
• Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells

  2024cites this paper
• Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers

  2024cites this paper
• Resveratrol amplifies the anti-tumor effect of α-PD-1 by altering the intestinal microbiome and PGD2 content

  2024cites this paper
• Acute remote ischemic conditioning enhances (CD3+)- but not (FoxP3+)-T-cell invasion in the tumor center and increases IL 17 and TNF-alpha expression in a murine melanoma model

  2024cites this paper
• The ending is not the end: Lymph node metastasis in oral squamous cell carcinoma.

  2024cites this paper
• MCRANet: MTSL-based connectivity region attention network for PD-L1 status segmentation in H&E stained images

  2024cites this paper
• Unravelling the Reasons Behind Limited Response to Anti-PD Therapy in ATC: A Comprehensive Evaluation of Tumor-Infiltrating Immune Cells and Checkpoints

  2024influential citation
• Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors

  2024cites this paper
• Cryoablation synergizes with anti-PD-1 immunotherapy induces an effective abscopal effect in murine model of cervical cancer

  2024cites this paper
• Efficient Biomarker for Immunotherapy: Measuring Broad Clones Effector Tumor Antigen-Specific T Cells in the Blood of Esophageal Cancer Patients.

  2024cites this paper
• Efficient Predictor for Immunotherapy Efficacy: Detecting Pan‐Clones Effector Tumor Antigen‐Specific T Cells in Blood by Nanoparticles Loading Whole Tumor Antigens

  2024cites this paper
• Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis

  2024cites this paper
• Enhancing Tumor-Specific immunity with SLdacA: A attenuated Salmonella-mediated c-di-AMP delivery system targeting the STING pathway.

  2024cites this paper
• Tumor-Infiltrating Immune Cells in Colorectal Cancer

  2024cites this paper
• Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy

  2024cites this paper
• Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma.

  2024cites this paper
• Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review

  2024cites this paper
• Immunotherapy and delivery systems for melanoma

  2024cites this paper
• The roles of genetic mutation and cytokines/chemokines in immune response and their association with uveal melanoma patient outcome

  2024cites this paper
• A multicomponent nanosystem for capturing circulating tumor cells from cancer patients with PD-L1 as an immunotherapy oncotarget.

  2024cites this paper
• Using Indirect Comparisons of Prospective, Randomized Trials to Make Therapeutic Decisions in Melanoma: Cross-Trial Comparisons as Surrogates for Proper Head-To-Head Studies?

  2024cites this paper
• Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells.

  2024cites this paper